🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/01/2008 | 21,86 | 22,64 | 20,71 | 21,44 | -7,39% | 8,83% | 5.570.700 |
| 02/01/2008 | 23,25 | 23,51 | 22,93 | 23,15 | -0,34% | 2,49% | 1.421.600 |
| 31/12/2007 | 23,20 | 23,64 | 22,80 | 23,23 | -1,02% | 3,62% | 1.518.200 |
| 28/12/2007 | 23,94 | 24,20 | 23,05 | 23,47 | -1,55% | 4,80% | 1.446.500 |
| 27/12/2007 | 24,85 | 24,95 | 23,77 | 23,84 | -3,79% | 4,75% | 1.172.400 |
| 26/12/2007 | 24,70 | 25,00 | 24,64 | 24,78 | -0,52% | 1,46% | 963.900 |
| 24/12/2007 | 24,91 | 25,00 | 24,57 | 24,91 | -0,04% | 1,73% | 446.500 |
| 21/12/2007 | 25,49 | 25,80 | 24,48 | 24,92 | -0,28% | 5,18% | 2.457.600 |
| 20/12/2007 | 25,00 | 25,10 | 24,58 | 24,99 | +0,68% | 2,08% | 1.375.000 |
| 19/12/2007 | 24,82 | 25,18 | 24,47 | 24,82 | -0,44% | 2,86% | 1.017.900 |
| 18/12/2007 | 24,44 | 25,06 | 24,28 | 24,93 | +2,21% | 3,19% | 1.392.000 |
| 17/12/2007 | 24,98 | 25,18 | 24,38 | 24,39 | -1,85% | 3,20% | 1.478.000 |
| 14/12/2007 | 24,75 | 25,01 | 24,48 | 24,85 | -0,28% | 2,14% | 1.103.700 |
| 13/12/2007 | 24,25 | 25,07 | 24,19 | 24,92 | -0,84% | 3,63% | 1.166.100 |
| 12/12/2007 | 25,79 | 25,94 | 24,75 | 25,13 | -0,16% | 4,61% | 2.128.700 |
| 11/12/2007 | 25,41 | 26,06 | 25,07 | 25,17 | -1,18% | 3,90% | 1.756.300 |
| 10/12/2007 | 25,49 | 25,72 | 25,09 | 25,47 | -0,08% | 2,47% | 1.619.500 |
| 07/12/2007 | 25,69 | 26,05 | 25,23 | 25,49 | -1,62% | 3,19% | 1.048.700 |
| 06/12/2007 | 25,45 | 26,06 | 25,10 | 25,91 | +1,61% | 3,77% | 1.615.300 |
| 05/12/2007 | 25,29 | 25,70 | 25,10 | 25,50 | +2,74% | 2,37% | 1.607.500 |
| 04/12/2007 | 24,95 | 25,22 | 24,70 | 24,82 | -0,72% | 2,08% | 1.571.000 |
| 03/12/2007 | 25,04 | 25,26 | 24,61 | 25,00 | -1,54% | 2,60% | 1.491.200 |
| 30/11/2007 | 25,30 | 25,58 | 25,05 | 25,39 | +1,16% | 2,09% | 1.482.700 |
| 29/11/2007 | 25,08 | 25,24 | 24,61 | 25,10 | -0,08% | 2,51% | 1.183.900 |
| 28/11/2007 | 24,55 | 25,24 | 24,35 | 25,12 | +3,72% | 3,63% | 1.796.100 |
| 27/11/2007 | 24,11 | 24,54 | 23,54 | 24,22 | +1,94% | 4,15% | 1.796.900 |
| 26/11/2007 | 24,08 | 24,53 | 23,67 | 23,76 | -1,00% | 3,57% | 1.215.500 |
| 23/11/2007 | 23,51 | 24,10 | 23,35 | 24,00 | +1,95% | 3,19% | 730.300 |
| 21/11/2007 | 23,10 | 23,82 | 22,95 | 23,54 | -4,19% | 3,77% | 3.420.500 |
| 20/11/2007 | 25,35 | 25,86 | 23,87 | 24,57 | -2,03% | 7,85% | 2.820.600 |